Cognate Bioservices, Inc.;NorthWest Biotherapeutics, Inc.;REVIMMUNE, INC.;The Regents of the University of California
发明人:
申请号：
EP14859634.9
公开号：
EP3065772A4
申请日:
2014.11.05
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
